Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 |
| clinicaltrials |
| NCT03750513 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07599371 | A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 0 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | active not recruiting | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05283109 | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM(ETAPA I) | active not recruiting | Phase 1 | 24 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04540107 | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | recruiting | Phase 1 | 300 | Susan ChangOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM(GBM 001) | recruiting | Phase 1 | 11 | Shayan Moosa, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03383978 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma(CAR2BRAIN) | recruiting | Phase 1 | 42 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03961971 | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | active not recruiting | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05366179 | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | recruiting | Phase 1 | 36 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05917145 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | recruiting | Phase 1 | 94 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | active not recruiting | Phase 1 | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06126744 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252(PuMP) | recruiting | Phase 1 | 51 | Duke UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients(STAR-GBM) | recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05168423 | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | active not recruiting | Phase 1 | 67 | University of PennsylvaniaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05413304 | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | active not recruiting | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06482905 | Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | recruiting | Phase 1 | 52 | Tcelltech Inc.INDUSTRY | 2 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma(APIC-RG) | not yet recruiting | Phase 1 | 24 | Ming YangOTHER | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2026source: clinicaltrials